The tumor variant burden is an important determinant of tumor antigenicity, and a gene variation is essential if it contributes greatly to affect the whole tumor variation profile.5 We found a significant association of MUC16 variation with elevated tumor variant burden and prolonged PFS and OS during ICI treatment in pancancer and specifically in NSCLC, suggesting that MUC16 might be an important component of the immunogenetic landscape and should be integrated into multiomics for precise selection of patients to receive ICI. Here, MUC16 is linked to neoplasm.